目的 統(tǒng)計分析2020年1月—2024年6月天津市寶坻區(qū)人民醫(yī)院新型抗腫瘤藥物的使用情況，分析其使用趨勢，為醫(yī)院新型抗腫瘤藥物的科學(xué)管理和臨床合理用藥提供參考。方法 采用世界衛(wèi)生組織推薦的限定日劑量（DDD）分析方法，計算每種新型抗腫瘤藥物的用藥頻度（DDDs）、日均費用（DDC），并對藥物的銷售金額和DDDs分別進行排序，計算其排序比（B/A）。結(jié)果 2020年1月—2024年6月天津市寶坻區(qū)人民醫(yī)院新型抗腫瘤藥物共30個品種，其中15種小分子靶向藥物15種大分子單克隆抗體類藥物，銷售金額和使用頻率均以大分子單克隆抗體類新型抗腫瘤藥物為主，占比90%以上。其中卡瑞利珠單抗使用的同步性最好，除2022年利妥昔單抗外，其余藥物DDC均呈下降趨勢。結(jié)論 天津市寶坻區(qū)人民醫(yī)院新型抗腫瘤藥物使用基本合理。

Objective To analyze the use of new antitumor drugs in Tianjin Baodi Hospital from January 2020 to June 2024, and analyze their use trend, so as to provide reference for the scientific management and clinical rational drug use of new antitumor drugs in the hospital. Methods Using the analysis method of defined daily dose (DDD) recommended by the World Health Organization (WHO), the medication frequency (DDDs) and average daily cost (DDC) of each hepatoprotective drugs were calculated, and the sales amount and DDDs of drugs were ranked, respectively, and the ranking ratio was calculated. Results From January 2020 to June 2024, Tianjin Baodi District People’s Hospital has a total of 30 types of new anti-tumor drugs, including 15 small-molecule targeted drugs and 15 large-molecule monoclonal antibody drugs. The sales sum and frequency of use are mainly large-molecule monoclonal antibody novel anti-tumor drugs, accounting for more than 90%. Among them, the use of carrilizumab had the best synchronization, and except for rituximab 2022, the DDC of other drugs showed a downward trend. Conclusion The use of new antitumor drugs in Tianjin Baodi Hospital is basically reasonable.

R979.1

國家抗腫瘤藥物臨床應(yīng)用監(jiān)測網(wǎng)腫瘤規(guī)范化診療中青年研究基金項目（DSS-YSF-2023002）